Go Pro
NASDAQ:IVF

INVO Fertility Q1 2026 Earnings Report

INVO Fertility logo
$0.97 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.94 -0.03 (-3.30%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INVO Fertility EPS Results

Actual EPS
-$3.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

INVO Fertility Revenue Results

Actual Revenue
$2.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

INVO Fertility Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

INVO Fertility Earnings Headlines

INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 60.9% in August
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More INVO Fertility Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like INVO Fertility? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INVO Fertility and other key companies, straight to your email.

About INVO Fertility

INVO Fertility (NASDAQ:IVF). is a medical technology and fertility services company focused on expanding access to in vitro fertilization (IVF) and related assisted reproductive technologies. The company’s primary product is INVOcell, an intravaginal culture system designed to incubate eggs and embryos inside a woman’s body during part of the IVF process, under the supervision of a fertility professional.

INVO Fertility seeks to make fertility treatment more accessible through a combination of medical devices, clinical services, and fertility centers. Its business model includes commercializing INVOcell, supporting clinics that use the technology, and developing or operating fertility treatment centers that provide services such as evaluation, egg retrieval, embryo culture, and embryo transfer.

The company was formerly known as INVO Bioscience and adopted the INVO Fertility name as it expanded its focus beyond device commercialization toward a broader fertility-care platform. INVOcell has received regulatory clearance in the United States and is also marketed in selected international markets, subject to applicable regulatory requirements. The company’s activities have primarily centered on the United States, with additional commercial and clinical opportunities pursued internationally.

View INVO Fertility Profile